Analysis of circulating tumor cells in prostate cancer. Predicting response to taxanes: A Pilot Study
||Benjamin Levy, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
Prostate cancer is the most commonly diagnosed cancer in American males and is the second leading cause of cancer related death in the United States in men. Treatment options for metastatic prostate cancer are varied and constantly changing. While initial suppression of male hormones is highly effective and provides disease control in over 80% of patients, the majority of patients will ultimately progress to a state where patients are not responsive to hormones and therefore resulting in extreme illness and eventual death.
The taxanes (ie. Docetaxel) have recently emerged as the first class of drugs used for this cancer, to improve survival for metastatic hormone (castrate) resistant prostate cancer. The main goal of this study is to investigate the molecular basis of clinical response to docetaxel chemotherapy in patients with hormone resistant castrate cancer (CRPC).
- Age 21 and older
- Histologic diagnosis (recent or remote) of prostate glandular tumor.
- Metastatic prostate defined by abnormal CT or MRI and/or abnormal bone scan.
- Patients will have castrate resistant prostate cancer as defined as clinical progression on CT or MRI scan and/or bone scan or biochemical progression by PSA, as defined by a rising PSA on 3 serial determinations over a period of ³ 2 weeks while on hormonal therapy with a testosterone level less than 50ng/dl.
Please call for more informations